Phase I Study of Low Dose 5-Aza-2'-Deoxycytidine [decitabine] Administered Daily for 5 Days Every Other Week for Patients With Relapsed or Refractory Acute Lymphocytic Leukemia.

Trial Profile

Phase I Study of Low Dose 5-Aza-2'-Deoxycytidine [decitabine] Administered Daily for 5 Days Every Other Week for Patients With Relapsed or Refractory Acute Lymphocytic Leukemia.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Nov 2014

At a glance

  • Drugs Decitabine (Primary) ; Cyclophosphamide; Dexamethasone; Doxorubicin; Vincristine
  • Indications Acute lymphoblastic leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 27 Jan 2014 Planned End Date changed from 1 Jul 2014 to 1 Jul 2015 as reported by ClinicalTrials.gov record.
    • 24 Jan 2013 Planned end date changed from 1 Jul 2013 to 1 Jul 2014 as reported by ClinicalTrials.gov.
    • 17 Jan 2012 Planned end date changed from 1 Jul 2012 to 1 Jul 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top